| [1] Meletis J, Viniou N, Terpos E.Novel agents for the management of myelodysplastic syndromes.Med Sci Monit. 2006;12(9):RA194-206.[2] Srinivasan S, Schiffer CA.Current treatment options and strategies for myelodysplastic syndromes.Expert Opin Pharmacother. 2008;9(10):1667-1678.[3] Daskalakis M, Nguyen TT, Nguyen C,et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment.Blood. 2002;100(8):2957-2964.[4] Dhodapkar M, Grill J, Lust JA.Abnormal regional hypermethylation of the calcitonin gene in myelodysplastic syndromes.Leuk Res. 1995;19(10):719-726.[5] Kantarjian H, Issa JP, Rosenfeld CS,et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.Cancer. 2006;106 (8):1794-1803.[6] Wijermans PW, Lübbert M, Verhoef G,et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.Ann Hematol. 2005;84 Suppl 1: 9-17.[7] Nimer SD.Myelodysplastic syndromes.Blood. 2008;111(10): 4841-4851.[8] Epling-Burnette PK, List AF.Advancements in the molecular pathogenesis of myelodysplastic syndrome.Curr Opin Hematol. 2009;16(2):70-76.[9] Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group.Cancer Genet Cytogenet. 1988;32(1):1-10.[10] Morel P, Hebbar M, Lai JL,et al. Cytogenetic analysis has strong independent prognostic value in de novo myelodysplastic syndromes and can be incorporated in a new scoring system: a report on 408 cases.Leukemia. 1993;7(9): 1315-1323.[11] Solé F, Espinet B, Sanz GF,et al.Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.Br J Haematol. 2000;108(2):346-356.[12] Herman JG, Baylin SB.Gene silencing in cancer in association with promoter hypermethylation.N Engl J Med. 2003;349(21):2042-2054.[13] El-Osta A. The rise and fall of genomic methylation in cancer. Leukemia. 2004;18(2):233-237.[14] Tien HF, Tang JH, Tsay W,et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation.Br J Haematol. 2001; 112(1):148-154.[15] Lakshmikuttyamma A, Scott SA, DeCoteau JF,et al. Reexpression of epigenetically silenced AML tumor suppressor genes by SUV39H1 inhibition.Oncogene. 2010; 29(4):576-588.[16] Fang MS,Long SP,Li L,et al.Jinggangshan Daxue Xuebao: Ziran Kexueban. 2010;31(3):102-103.方木水,龙生平,黎龙,等.地西他滨治疗骨髓增生异常综合征转急性白血病1例并文献复习[J].井冈山大学学报:自然科学版,2010, 31(3):102-103.[17] Cutler C.Patient selection for transplantation in the myelodysplastic syndromes.Hematol Oncol Clin North Am. 2010;24(2):469-476.[18] Greenberg PL, Attar E, Bennett JM,et al. NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.J Natl Compr Canc Netw. 2011;9(1):30-56.[19] Zhang Q,Bai H,Wang CB,et al.Linchuang Xueyexue Zazhi. 2008;21(3):165-166.张茜,白海,王存邦,等.HLA相合同胞异基因造血干细胞移植治疗儿童MDS转变的AML 1例[J].临床血液学杂志,2008,21(3): 165-166. |
